Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Italian Institute of Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"ITALY","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"PsychoGenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Undisclosed","date":"July 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"PsychoGenics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Sapienza University of Rome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics Announces Sponsored Research Agreement with The Sapienza University of Rome, Italy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Evotec","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by IAMA Therapeutics

    Menu

    IAMA Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              IAMA Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

              Details:

              IAMA-6 is an orally administered small molecule therapeutic designed to directly target and inhibit NKCC1-associated neuronal hyperexcitability. It is under phase 1 clinical development for the treatment of Autism & Epilepsy.

              Lead Product(s): IAMA-6

              Therapeutic Area: Neurology Product Name: IAMA-6

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 23, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IAMA Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of A...

              Details:

              IAMA-6 is an orally administered small molecule therapeutic targeting NKCC1. Its clinical trial application is approved after the preclinical studies for the treatment of autism and epilepsy.

              Lead Product(s): IAMA-6

              Therapeutic Area: Neurology Product Name: IAMA-6

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 20, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IAMA Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec

              Details:

              Evotec will provide IAMA with preclinical and clinical services to support the anticipated Phase 1 clinical trial to investigate IAMA's lead program IAMA-6, a small molecule therapeutic targeting NKCC1 for the treatment of autism and epilepsy.

              Lead Product(s): IAMA-6

              Therapeutic Area: Neurology Product Name: IAMA-6

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Evotec

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 02, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IAMA Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IAMA Therapeutics Announces Sponsored Research Agreement with The Sapienza University of Rome, Italy

              Details:

              The collaboration aims to investigate the efficacy of selective chloride modulator, IAMA-6, in reducing neuronal excitability and hippocampal activity in human tissue with epilepsies and neurodevelopmental disorders, including Dravet syndrome, FCD, and Rett syndrome.

              Lead Product(s): IAMA-6

              Therapeutic Area: Neurology Product Name: IAMA-6

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Sapienza University of Rome

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IAMA Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome

              Details:

              PsychoGenics will evaluate the anti-seizure efficacy of first-in-class selective-NKCC1 inhibitors, which restore the physiological hyperpolarizing and inhibitory GABAergic transmission in a preclinical model of Dravet syndrome.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: PsychoGenics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IAMA Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics

              Details:

              Under the agreement, PsychoGenics will evaluate the preclinical anti-seizure efficacy of first-in-class selective-NKCC1 inhibitors, which aims to reduce intracellular chloride concentration and restore the physiological hyperpolarizing and inhibitory GABAergic transmission.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: PsychoGenics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IAMA Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022

              Details:

              IAMA-6 is a first-in-class selective-NKCC1 inhibitor that modulates the intracellular chloride, reducing the depolarizing strength of GABAA receptors to the levels required to restore the inhibitory transmission.

              Lead Product(s): IAMA-6

              Therapeutic Area: Neurology Product Name: IAMA-6

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IAMA Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry

              Details:

              IAMA-6 is a preclinical stage, a first-in-class selective-NKCC1 inhibitor that modulates the intracellular chloride, reducing the depolarizing strength of GABAA receptors to the levels required to restore the inhibitory transmission.

              Lead Product(s): IAMA-6

              Therapeutic Area: Neurology Product Name: IAMA-6

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 24, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IAMA Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery

              Details:

              Under the collaboration with the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology), they will design and profile new classes of compounds targeting cation cotransporters in the CNS area.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Italian Institute of Technology

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Bora Pharmaceuticals- Making success more certain.
              AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
              Post Enquiry
              POST ENQUIRY